A Study of LY3561774 in Participants With Mixed Dyslipidemia (PROLONG-ANG3)

J3F-MC-EZCB -

This is a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 injected simultaneously at various doses in participants who take a statin and still have high cholesterol and/or high triglycerides.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
High Cholesterol and/or High Triglycerides
What the trial is testing?
LY3561774
Could I receive a Placebo?
Yes
Enrollment Goal
204
Trial Dates
Jul 20, 2022 - May 23, 2024
How long will I be in the trial?
The study will last about 58 weeks and may include up to 13 visits.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Be on a statin and have high cholesterol and/or high triglycerides

Participants Must Not:

  • Have uncontrolled diabetes

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources

Cardiovascular Research

To learn more about the types of cardiovascular disease and ongoing clinical trials we conduct in this area, visit our Cardiovascular Disease Research page.

Cardiovascular Research

Clinical Trial Information

A clinical trial helps us learn if a new potential medicine or treatment works and how it works. Clinical trials are also called clinical research studies. To learn more about what to expect when taking part in a clinical trial, visit our Clinical Trial Information page.